No Data
Bidang Pharmaceutical (688073.SH): The actual controller Dai Lan has proposed that the company repurchase shares again.
Gelonghui, on November 25, reported that Bid Pharmaceutical (688073.SH) announced that the company's board of directors received a letter from Mrs. Dai Lan, the actual controller, chairman, and general manager of the company, on November 24, 2024, proposing that Shanghai Bid Pharmaceutical Technology Co., Ltd. buy back a portion of its issued ordinary shares (A-shares) through the centralized bidding trading method in the Shanghai Stock Exchange trading system. The repurchased shares will be used for the company's stock-based incentive plan or employee stock ownership plan, or to cancel and reduce the company's registered capital. The total amount of funds for the buyback will not be less than 50 million yuan.
Bide Pharmatech Co., Ltd.'s (SHSE:688073) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Bide Pharmaceuticals: third quarter report 2024
Third Quarter Report 2024
Bede Pharmaceuticals (688073.SH) released its performance for the first three quarters, with a net income of 83.85 million yuan, a year-on-year decrease of 26.05%.
Bide Pharmaceutical (688073.SH) disclosed its third quarter report for 2024. During the reporting period, the company achieved revenue of 8.1...
BiDe Pharmaceutical (688073.SH): The net income in the first three quarters was 83.8539 million yuan, a year-on-year decrease of 26.05%.
GElonghui Oct. 23 - Bide Pharmaceuticals (688073.SH) announced that the company's revenue in the first three quarters was 0.811 billion yuan, a year-on-year increase of 0.79%; net income attributable to shareholders of the listed company was 83.8539 million yuan, a year-on-year decrease of 26.05%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 72.3904 million yuan, a year-on-year decrease of 40.18%; basic earnings per share were 0.94 yuan.
Are Bide Pharmatech Co., Ltd.'s (SHSE:688073) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?No Data
No Data
